Screener
BridgeBio Pharma BBIO Reportable Segment — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
| Total other expense, net | (60,599) | (65,236) |
| Net loss | (166,555) | (169,608) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,512 | 2,186 |
| Segment net loss attributable to common stockholders of BridgeBio | $(164,043) | $(167,422) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — net loss?
- BridgeBio Pharma (BBIO) reported reportable segment — net loss of -$166.56M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — net loss changed year-over-year?
- BridgeBio Pharma's reportable segment — net loss increased by 1.8% year-over-year, from -$169.61M to -$166.56M.
- What does reportable segment — net loss mean?
- This represents the total bottom-line loss for the reportable segment after all operating expenses, taxes, and non-operating items have been deducted. It serves as the primary indicator of the segment's overall financial performance and sustainability. For high-growth biotech firms, this often reflects heavy investment in R&D relative to current revenue generation.
Ask your AI about BridgeBio Pharma's reportable segment — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude